Mira announces results from studies of Ketamir-2’s oral bioavailability

MIRA Pharmaceuticals announced results from recent studies that indicate Ketamir-2’s oral bioavailability is predicted to be approximately 80%. MIRA recently unveiled its revolutionary product, Ketamir-2, which is designed to potentially reshape the landscape of depression treatment. Ketamir-2 lead developer Adam Kaplin, President and Chief Scientific Officer, commented: “Ketamir-2, an innovative analog of Ketamine developed as an oral formulation, signifies a breakthrough for Major Depressive Disorder and MDSI. Tailored for convenient home use, it offers administration ease and aims for fewer side effects, eliminating the need for clinical supervision associated with existing treatments like Spravato.” Recent laboratory invitro studies of the CaCO-2 model of human intestinal drug absorption suggested Ketamir-2’s superior absorption when taken by mouth compared to Ketamine, with key findings indicating a dramatic 41% net absorption. Given oral Ketamine’s previously determined 23% bioavailability when taken by mouth, Ketamir-2’s adjusted oral bioavailability based on the CaCO-2 results is predicted to be around 80%1. This bioavailability is more than double that of oral or intranasal absorption of ketamine, promising a potential shift to oral, home administration, granting patients greater autonomy, convenience, and accessibility to effective depression treatment.